Semaglutide reduces excess body fat in people with obesity
Findings suggest drug has potential to reduce risk of heart disease, diabetes and stroke
2021-03-20
(Press-News.org) WASHINGTON--In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"Our findings suggest that semaglutide, through body weight loss and improvement of body composition, has the potential to reduce the risk of heart disease, diabetes and stroke in people with overweight or obesity," said lead researcher John Wilding, D.M., F.R.C.P., of the University of Liverpool.
Obesity poses many health risks. Excess fat in the abdominal area, particularly fat in and around abdominal organs, also called visceral fat, contributes to major causes of death and disability, including heart attacks, strokes, high blood pressure, cancer, fatty liver disease and diabetes.
The study, called STEP 1, included 1,961 adults with a body mass index (BMI) of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher, without diabetes. A person is classified as overweight if their BMI is 25 to 29.9, and the range for obesity is a BMI of 30 or more.
The study participants were randomly assigned to inject themselves once weekly for 68 weeks with either 2.4 milligrams of semaglutide or a placebo. Semaglutide, already approved by the U.S. Food and Drug Administration at the lower dose of 1 mg weekly as a treatment for type 2 diabetes, is a synthetic version of the naturally occurring hormone glucagon-like peptide 1 (GLP1). It acts on appetite centers in the brain and in the gut, and produces feelings of fullness.
As part of the study, the researchers used dual-energy absorptiometry (DEXA), a technique that is widely used clinically to assess body composition, to monitor the effects of therapy on total body fat and fat around the stomach area in 140 of the participants.
They found treatment with semaglutide improved body composition by reducing excess body fat, including abdominal fat, and increasing the proportion of lean body mass, or the amount of weight someone carries that is not body fat. The more body weight a participant lost, the greater the improvement in body composition.
In February 2021, the researchers published findings from the STEP 1 trial in The New England Journal of Medicine showing that patients who injected semaglutide lost close to 15% of their body weight, on average, compared with 2.4% among patients receiving the placebo. More than one-third of participants receiving semaglutide lost more than 20% of their weight. Many patients experienced improvements in risk factors for heart disease, blood sugar levels and quality of life.
INFORMATION:
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
ELSE PRESS RELEASES FROM THIS DATE:
2021-03-20
WASHINGTON--Patients hospitalized with COVID-19 have worse outcomes if they have high blood sugar, or hyperglycemia, regardless of whether they have diabetes, a new study finds. The researchers will present their results, of the first known study of the impact of hyperglycemia on a largely Black patient population with the novel coronavirus, at ENDO 2021, the Endocrine Society's annual meeting.
The investigators found that patients with COVID-19 who had hyperglycemia on admission to the hospital were more likely than those with normal glucose (sugar) to require a breathing machine or admission to the intensive care unit (ICU). These patients also were reportedly likelier to have kidney injury and to die ...
2021-03-20
WASHINGTON--More patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for thyroid eye disease, teprotumumab (Tepezza), according to a small study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
Teprotumumab, approved by the U.S. Food and Drug Administration in January 2020, is the first and only drug to be approved for thyroid eye disease. In two clinical trials conducted prior to FDA approval of the drug, otologic symptoms were reported in 10 percent of patients. The new study found the rate could be as high as 65 percent.
The treatment is administered to patients once every three weeks for a total of eight infusions. It ...
2021-03-20
WASHINGTON--People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation's Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod, the first tubeless, wearable insulin pump, will be presented at ENDO 2021, the Endocrine Society's annual meeting.
The Omnipod 5 System underwent three months of at-home testing in 128 adults and adolescents ages 14 to 70 years and 112 children ages 6 to less than 14 years. All study participants have type 1 diabetes and were first followed for two weeks using their standard therapy, either multiple daily insulin injections ...
2021-03-20
WASHINGTON--Higher levels of the stomach-derived hormone ghrelin, which stimulates appetite, predict a greater preference for smaller immediate monetary rewards over larger delayed financial rewards, a new study finds. The study results will be presented at ENDO 2021, the Endocrine Society's annual meeting.
This research presents novel evidence in humans that ghrelin, the so-called "hunger hormone," affects monetary decision making, said co-investigator Franziska Plessow, Ph.D., assistant professor of medicine at Massachusetts General Hospital and Harvard Medical School, Boston. She said recent research findings in rodents suggested that ghrelin may play a part in impulsive choices and behaviors.
"Our results indicate that ghrelin might play a broader role than ...
2021-03-20
WASHINGTON--Nearly one in five U.S. children and teenagers has obesity, and statistics show a higher prevalence of obesity in certain ethnicities, such as Hispanics and Blacks. Now results of a study being presented at ENDO 2021, the Endocrine Society's annual meeting, suggest that Spanish as a family's primary language is a predictor of childhood obesity, regardless of ethnicity.
The prevalence of obesity among children and teens from Spanish-speaking households in the nation was 24.4 percent, approximately 50 percent higher than those from English-speaking households, according to results of a new analysis of the U.S. National Health and Nutrition Examination Survey. This survey examines a nationally representative sample ...
2021-03-20
Tokyo, Japan - Researchers from Tokyo Metropolitan University have devised and implemented a simplified algorithm for turning freely drawn lines into holograms on a standard desktop CPU. They dramatically cut down the computational cost and power consumption of algorithms that require dedicated hardware. It is fast enough to convert writing into lines in real-time, and makes crisp, clear images that meet industry standards. Potential applications include hand-written remote instructions superimposed on landscapes and workbenches.
Flying cars, robots, spaceships...whatever sci-fi future you can imagine, there is always a common feature: holograms. ...
2021-03-20
Researchers from Columbia University and Temple University published a new paper in the Journal of Marketing that examines how choice architecture can reduce socioeconomic disparities.
The study, forthcoming in the Journal of Marketing, is titled "Do Nudges Reduce Disparities? Choice Architecture Compensates for Low Consumer Knowledge" and is authored by Kellen Mrkva, Nathaniel Posner, Crystal Reeck, and Eric Johnson.
As Mrkva explains, "Our research demonstrates that people with low socioeconomic status (SES), low numerical ability, and low knowledge are most impacted by nudges. As a result, 'good nudges,' designed to encourage ...
2021-03-19
It's estimated that an average-sized wastewater treatment plant serving roughly 400,000 residents will discharge up to 2,000,000 microplastic particles into the environment each day. Yet, researchers are still learning the environmental and human health impact of these ultra-fine plastic particles, less than 5 millimeters in length, found in everything from cosmetics, toothpaste and clothing microfibers, to our food, air and drinking water.
Now, researchers at New Jersey Institute of Technology have shown that ubiquitous microplastics can become 'hubs' for antibiotic-resistant bacteria ...
2021-03-19
ROCHESTER, Minn. -- Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
The researchers investigated the use of genomic databases and found that tumor mutation burden was significantly inflated in Black patients compared to White patients.
As a result of the study, clinicians who are using public genomic databases need to be aware of the potential for inflated tumor mutation burden values and how that may affect therapy selection and outcomes, especially for patients from underrepresented groups.
Clinicians use biomarkers, which are indicators of a disease or condition, to determine ...
2021-03-19
BOSTON - Researchers have used a genetic engineering strategy to dramatically reduce levels of tau--a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer's disease--in an animal model of the condition. The results, which come from investigators at Massachusetts General Hospital (MGH) and Sangamo Therapeutics Inc., could lead to a potentially promising treatment for patients with this devastating illness.
As described in Science Advances, the strategy involves a gene regulation technology called zinc finger protein transcription ...
LAST 30 PRESS RELEASES:
[Press-News.org] Semaglutide reduces excess body fat in people with obesity
Findings suggest drug has potential to reduce risk of heart disease, diabetes and stroke
